Cetrelimab Biosimilar - Research Grade

Name: Cetrelimab Biosimilar - Research Grade
SKU: ICH5434-10mg
Price: 2654 USD
Availability: OutOfStock

Out of stock

Only %1 left

SKU

ICH5434-10mg

Add to Compare

Be the first to review this product

Cetrelimab Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>90% by SDS-PAGE

Species Reactivity

Human

Target

PDCD1

Concentration

>1mg/ml

Isotype

IgG4 - kappa

Host

CHO Cells

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q15116

Shipping Conditions

Blue ice

Background

This is a research-grade biosimilar of cetrelimab, supplied as an unconjugated, non-therapeutic analog of the originator anti-PD-1 antibody for research use only. It is not a clinical drug. The molecule is built around the same target as the originator, human PD-1 (PDCD1), and is provided as a human IgG4-kappa immunoglobulin, matching the isotype of the reference antibody. Cetrelimab is a checkpoint inhibitor developed to block PD-1 engagement by its ligands PD-L1 and PD-L2, thereby relieving inhibitory signaling on T cells. As a biosimilar reagent, this product is intended to reproduce the target-binding behavior of the originator for functional and comparative studies rather than for dosing patients. It is offered at research grade with low endotoxin, and is suitable as a binding, blocking, or reference standard in assays that interrogate the PD-1/PD-L1 axis. Because it reproduces a human IgG4 framework, it is well suited to human-target in-vitro systems, isotype-matched comparisons, and characterization work supporting antibody engineering and immuno-oncology research programs. PD-1 (programmed cell death protein 1, gene PDCD1; UniProt Q15116) is an inhibitory immune checkpoint receptor expressed on activated T cells, B cells, NK cells, and other immune subsets. Engagement of PD-1 by its ligands PD-L1 and PD-L2 recruits phosphatases that dampen T-cell receptor and costimulatory signaling, promoting T-cell exhaustion and peripheral tolerance. Tumors and chronically infected tissues co-opt this pathway to suppress effector responses. Blocking PD-1 prevents ligand engagement, restoring proliferation, cytokine production, and cytotoxic activity of exhausted or suppressed T cells. This axis is a central node in cancer immunotherapy, and antibodies against PD-1 are widely used to reactivate antitumor immunity. The receptor's biology makes it a key target for functional immuno-oncology studies of checkpoint blockade and T-cell reactivation.

Other Names

Protein PD-1, hPD-1, Programmed cell death protein 1, PD1

Purification Method

This monoclonal antibody was purified using Protein A

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Storage

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.